Novel findings on GRB2 and SOS1 could pave the way for cancer treatments

The Eu­ro­pean Med­i­cines Agency’s hu­man med­i­cines com­mit­tee (CHMP) to­day rec­om­mend­ed No­vavax’s adapt­ed Nu­vax­ovid boost­er vac­cine for pre­vent­ing the Omi­cron XBB.1.5 sub­vari­ant of the coro­n­avirus in

UK non-prof­it and med­ical re­search group LifeArc is look­ing to push fur­ther in­to rare dis­ease re­search, so it has cre­at­ed a “chal­lenge” to try and